Diabetes Drug's heart benefits probed in tiny, terminated study
NCT ID NCT05139914
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aimed to see how dapagliflozin, a diabetes drug, affects blood vessel health in people with type 2 diabetes. Researchers planned to measure blood pressure and other markers of vascular function. However, the trial was terminated early and only enrolled 4 participants, so the findings are very limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dapagliflozin
- What this could lead to
- If successful, this could help explain how dapagliflozin protects the heart and blood vessels in people with type 2 diabetes.
- What could go wrong
- The trial was terminated early with only 4 participants, so results are very limited and may not be reliable. It was a small, early-stage mechanistic study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
BU School of Medicine Evans 748
Boston, Massachusetts, 02118, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a heart drug tame blood sugar and weight in diabetes?
- Can a puff of insulin replace a needle for diabetes?
- Could a quick insulin shot stop Steroid-Induced blood sugar spikes?
- Can a puff of insulin replace a daily shot for diabetes?
- Could a Dairy-Rich diet tame type 2 diabetes?
- Can a traditional herbal remedy tame type 2 diabetes?